Oral T-therapy

* Oral TRT, particularly testosterone undecanoate (TU), offers notable convenience. TU is absorbed via the lymphatic system, bypassing first-pass hepatic metabolism, making it a promising agent for TRT. Its absorption, however, is influenced by dietary factors, such as lipid intake, thus the...

https://www.mdpi.com/2305-6320/13/1/1# Abstract Symptomatic male hypogonadism, defined by low serum testosterone with associated clinical symptoms, is increasingly treated with testosterone replacement therapy. Traditional oral formulations were limited by hepatotoxicity and poor...

Shalin Shah is the founder & CEO of Marius Pharmaceuticals, the company that partnered with $HIMS to launch oral testosterone (KYZATREX). We discuss how the partnership came about, the benefits of teaming up with HIMS, and the future of TRT. Chapters (00:41) Origin of the partnership...

*m Mean sexual activity scores rose from 2.43 points at baseline to 4.28 points at day 105 for men receiving oral testosterone undecanoate, a 1.85-point improvement during the trial. “Just to put this in perspective, when we look at the TRAVERSE trial, that change [in sexual activity score] was...

Modern patients want simple, effective treatment options. KYZATREX® offers oral testosterone therapy with proven efficacy—and none of the mess, pain, or liver strain of older options. .Join Dr. John Mulhall for a deep dive into the science and patient selection for KYZATREX®. John P...

Principle investigator Dr. Irwin Goldstein of course! https://clinicaltrial.be/fr/details/284355?per_page=100&only_recruiting=0&only_eligible=0&only_active=0 Description of the study This study is being conducted in an unblinded fashion because the primary endpoint is pharmacokinetic...

https://www.biospace.com/press-releases/marius-pharmaceuticals-announces-kyzatrex-testosterone-undecanoate-ciii-capsules-availability-through-thrive-expanding-mens-health-solutions RALEIGH, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals is pleased to announce that Thrive, a...